ofatumumab oncology
Selected indexed studies
- Ofatumumab. (Drugs, 2010) [PMID:20481657]
- Ofatumumab. (MAbs, 2009) [PMID:20068404]
- Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? (Clin Exp Immunol, 2024) [PMID:38642912]
_Worker-drafted node — pending editorial review._
Connections
ofatumumab oncology is a side effect of
Sources
- Ofatumumab. (2010) pubmed
- Ofatumumab. (2009) pubmed
- Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? (2024) pubmed
- New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are? (2022) pubmed
- Ofatumumab. (2010) pubmed
- Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study. (2025) pubmed
- The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. (2020) pubmed
- B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. (2024) pubmed
- Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. (2019) pubmed
- Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. (2017) pubmed